Clinical Trial Update: HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating HRS-4642 in combination with nimotuzumab for recurrent or metastatic pancreatic ductal adenocarcinoma is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• HRS-4642
• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: West China Hospital | Conditions: Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1, Phase 2 | Status: RECRUITING